These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24634375)

  • 1. SETting OP449 into the PP2A-activating drug family.
    Neviani P; Perrotti D
    Clin Cancer Res; 2014 Apr; 20(8):2026-8. PubMed ID: 24634375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
    Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
    Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
    Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
    Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
    Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
    J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
    Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
    Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
    Arriazu E; Pippa R; Odero MD
    Front Oncol; 2016; 6():78. PubMed ID: 27092295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
    Switzer CH; Cheng RY; Vitek TM; Christensen DJ; Wink DA; Vitek MP
    Oncogene; 2011 Jun; 30(22):2504-13. PubMed ID: 21297667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
    Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
    Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
    Fujiwara N; Kawasaki H; Yabe R; Christensen DJ; Vitek MP; Mizuno T; Sato K; Ohama T
    J Vet Med Sci; 2013; 75(3):349-54. PubMed ID: 23131782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
    Cristóbal I; Manso R; González-Alonso P; Rojo F; García-Foncillas J
    Leukemia; 2015 Oct; 29(10):2117. PubMed ID: 26283451
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.
    Christensen DJ; Ohkubo N; Oddo J; Van Kanegan MJ; Neil J; Li F; Colton CA; Vitek MP
    J Immunol; 2011 Feb; 186(4):2535-42. PubMed ID: 21289314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
    Liu Y; He P; Liu F; Zhou N; Cheng X; Shi L; Zhu H; Zhao J; Wang Y; Zhang M
    Tumour Biol; 2014 Apr; 35(4):3421-30. PubMed ID: 24430359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
    J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
    Samanta AK; Chakraborty SN; Wang Y; Kantarjian H; Sun X; Hood J; Perrotti D; Arlinghaus RB
    Oncogene; 2009 Apr; 28(14):1669-81. PubMed ID: 19234487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
    Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
    Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.